Dasiglucagon + Dasiglucagon + Placebo
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Glucose Metabolism Disorders
Trial Timeline
Feb 1, 2023 → Feb 1, 2023
NCT ID
NCT04824872About Dasiglucagon + Dasiglucagon + Placebo
Dasiglucagon + Dasiglucagon + Placebo is a phase 2 stage product being developed by Zealand Pharma for Hypoglycemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04824872. Target conditions include Hypoglycemia, Glucose Metabolism Disorders.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04824872 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (INN imapextide) | MBX Biosciences | Phase 2 | 47 |
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 28 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Glucagon + Insulin | Abvance Therapeutics | Phase 1 | 25 |
| Nasal Glucagon + Intramuscular Glucagon | Eli Lilly | Phase 1 | 33 |
| Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg | Eli Lilly | Phase 2 | 52 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Eplerenone + Placebo | Johnson & Johnson | Pre-clinical | 23 |
| Sitagliptin phosphate + Placebo | Merck | Approved | 85 |
| Pasireotide | Novartis | Phase 1 | 33 |
| Dasiglucagon | Novo Nordisk | Phase 3 | 76 |
| Glucagen + Mayne Glucagon | Pfizer | Phase 1 | 32 |
| Pramlintide | Bristol Myers Squibb | Approved | 84 |
| dasiglucagon + placebo + GlucaGen HypoKit | Zealand Pharma | Phase 3 | 74 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 1 | 30 |
| ZP4207 + Glucagon | Zealand Pharma | Phase 1 | 30 |
| ZP4207 + Placebo | Zealand Pharma | Phase 1 | 30 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 3 | 74 |
| dasiglucagon + GlucaGen | Zealand Pharma | Phase 3 | 74 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 49 |